Log in

Relevant bibliographies by topics / Mrk 348 / Journal articles

To see the other types of publications on this topic, follow the link: Mrk 348.

Journal articles on the topic 'Mrk 348'

Author: Grafiati

Published: 9 March 2023

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Mrk 348.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Peck, Alison B., Heino Falcke, Christian Henkel, Karl M. Menten, Yoshiaki Hagiwara, Jack F. Gallimore, and James S. Ulvestad. "A flaring megamaser in Mrk 348." Symposium - International Astronomical Union 206 (2002): 434–37. http://dx.doi.org/10.1017/s0074180900222845.

Full text

Abstract:

We report new observations of the H2O megamaser in the Seyfert 2 galaxy Mrk 348. Following our initial detection in 2000 March using the Effelsberg 100 m telescope, a re-analysis of previous data on this source indicates that the maser was present but only marginally detectable in late 1997. Monitoring through late 2000 shows that the maser has again decreased to its original level. The H2O line is redshifted by ∼130 km s−1 with respect to the systemic velocity, is extremely broad, with a FWHM of 130 km s−1, and has no detectable high velocity components within 1500 km s−1 on either side of the strong line. Followup VLBA observations show that the maser emission emanates entirely from a region ≤0.25 pc in extent, toward the base of the radio jet.

APA, Harvard, Vancouver, ISO, and other styles

2

Riffel, R. A., O. L. Dors, M. Armah, T. Storchi-Bergmann, A. Feltre, G. F. Hägele, M. V. Cardaci, et al. "Chemical abundances in Seyfert galaxies – V. The discovery of shocked emission outside the AGN ionization axis." Monthly Notices of the Royal Astronomical Society: Letters 501, no. 1 (December 8, 2020): L54—L59. http://dx.doi.org/10.1093/mnrasl/slaa194.

Full text

Abstract:

ABSTRACT We present maps for the electron temperature in the inner kpc of three luminous Seyfert galaxies: Mrk 79, Mrk 348, and Mrk 607 obtained from Gemini Multi-Object Spectrograph-integral field unit observations at spatial resolutions of ∼110–280 pc. We study the distributions of electron temperature in active galaxies and find temperatures varying in the range from ∼8000 to $\gtrsim 30\, 000\,$K. Shocks due to gas outflows play an important role in the observed temperature distributions of Mrk 79 and Mrk 348, while standard photoionization models reproduce the derived temperature values for Mrk 607. In Mrk 79 and Mrk 348, we find direct evidence for shock ionization with overall orientation orthogonal to the ionization axis, where shocks can be easily observed as the active galactic nuclei radiation field is shielded by the nuclear dusty torus. This also indicates that even when the ionization cones are narrow, the shocks can be much wider angle.

APA, Harvard, Vancouver, ISO, and other styles

3

Capetti, A., D. J. Axon, F. D. Macchetto, and W. B. Sparks. "Radio Outflows and the Origin of the Narrow Line Region in Seyfert Galaxies." Symposium - International Astronomical Union 175 (1996): 230–31. http://dx.doi.org/10.1017/s0074180900080591.

Full text

Abstract:

Seven Seyfert galaxies, Mrk 3, Mrk 78, Mrk 348, Mrk 6, Mrk 573, NGC 3393, IRAS 04210+0400 and IRAS 11058-1131 (all Seyfert galaxies type 2 expect Mrk 6 which is a Seyfert 1.5) were observed with HST. For the first five objects images were taken with the FOC with filters centered on the emission lines [O II] and [O III]. For the remaining three galaxies WFPC2 observations were obtained in the [O III] and Hα lines.

APA, Harvard, Vancouver, ISO, and other styles

4

Riffel, Rogemar A., Oli L. Dors, Angela C. Krabbe, and César Esteban. "Electron temperature fluctuations in Seyfert galaxies." Monthly Notices of the Royal Astronomical Society: Letters 506, no. 1 (June 10, 2021): L11—L15. http://dx.doi.org/10.1093/mnrasl/slab064.

Full text

Abstract:

ABSTRACT We use Gemini GMOS-IFU observations of three luminous nearby Seyfert galaxies (Mrk 79, Mrk 348, and Mrk 607) to estimate the electron temperature (Te) fluctuations in the inner 0.4–1.1 kpc region of these galaxies. Based on Te determinations through the [O iii]λ5007/λ4363 emission line ratio of each spaxel, temperature variations are quantified by computing the integrated value of the temperature fluctuation parameter (t2) projected in the plane of the sky $t_{\rm A}^{\rm 2}$, for the first time in active galactic nuclei (AGNs). We find $t_{\rm A}^{\rm 2}$ values of 0.135, 0.039, and 0.015 for Mrk 79, Mrk 348, and Mrk 607, respectively, which are of the same order or larger than the maximum values reported in star-forming regions and planetary nebulae. Taking into account that $t_{\rm A}^{\rm 2}$ should be considered a lower limit of the total t2 in the nebular volume, the results suggest that the impact of such fluctuations on chemical abundance determinations can be important in some AGNs.

APA, Harvard, Vancouver, ISO, and other styles

5

Antón, Sónia, Andrew Thean, Ian Browne, and Alan Pedlar. "The orientation of the Seyfert Nucleus in Mrk 348." International Astronomical Union Colloquium 184 (2002): 289–90. http://dx.doi.org/10.1017/s0252921100030840.

Full text

Abstract:

AbstractWe present new data on Mrk348: 5 GHz data with MERLIN and infrared data with ISO. The radio properties of Mrk 348 are unusual among Seyfert galaxies, and we discuss the orientation of the AGN axis with respect to the line of sight.

APA, Harvard, Vancouver, ISO, and other styles

6

Marchese, E., V. Braito, J. N. Reeves, R. Della Ceca, A. Caccianiga, A. Markowitz, G. Risaliti, P. Severgnini, and T. J. Turner. "The variable ionized absorber in the Seyfert 2 Mrk 348." Monthly Notices of the Royal Astronomical Society 437, no. 3 (November 30, 2013): 2806–15. http://dx.doi.org/10.1093/mnras/stt2101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Xanthopoulos, Emily, Anita M. S. Richards, and Phil J. Diamond. "Merlin water maser observations of the Seyfert 2 galaxy Mrk 348." Symposium - International Astronomical Union 206 (2002): 438–41. http://dx.doi.org/10.1017/s0074180900222857.

Full text

Abstract:

MERLIN images of Mrk 348 at 22 GHz show H2O maser emission at 0.02–0.11 Jy, within ∼ 0.8 pc of the nucleus. This is the first direct confirmation that molecular material exists close to the Seyfert 2 nucleus. Mrk 348 was observed one month after Falcke et al. (2000) first identified the maser in single-dish spectra. The peak maser flux density has increased about threefold. The masing region is ≲ 0.6 pc in radius. The flux density of radio continuum emission from the core has been rising for about 2 years. The maser-core separation is barely resolved but at the 3σ significance level maser and continuum peaks are not coincident along the line of sight. The masers lie in the direction of the northern radio lobes and probably emanate from material shocked by a jet with velocity close to c although direct maser amplification of the core by masers tracing a Keplerian disc is not completely ruled out.

APA, Harvard, Vancouver, ISO, and other styles

8

Wang, J., J. S. Zhang, and Q. Guo. "Chandra and XMM–Newton Observations of H2O Maser Galaxy Mrk 348." Journal of Astrophysics and Astronomy 35, no. 3 (September 2014): 545–48. http://dx.doi.org/10.1007/s12036-014-9282-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Macchetto, F. Duccio. "HST Observations of Active Galactic Nuclei." Symposium - International Astronomical Union 194 (1999): 12–24. http://dx.doi.org/10.1017/s0074180900161674.

Full text

Abstract:

The HST has made many contributions to all areas of research in the field of AGN, and I have selected three topics where major progress in our understanding has been made over the last two years. The study of the NLR is key to understanding to what extent the unified model for AGN is applicable. In particular, understanding how the NLR is ionized and how its morphology is defined makes an important contribution to clarify the differences between Seyfert 1 and Seyfert 2. Work by Macchetto et al., Capetti et al., Axon et al., and Wilson et al. has helped clarify the picture. Our work on NGC 1068, Mrk 3, Mrk 7, Mrk 348, Mrk 6, and Mrk 573 has shown the following important properties: a) all AGN with a linear radio jet show emission-line morphology ([O III], [O II], Hα) which is aligned along the jet in a surrounding cocoon; b) those AGN with radio lobes show emission-line morphology which is filamentary and coincident with the position of the lobes; and c) in NGC 1068 and in Mrk 3 we have measured transverse velocities to the radio-jet as large as 1700 km s−1. These velocities measured at different positions across the radio-jet show an almost perfect velocity ellipsoid, indicating that the cocoon around the jet is expanding, compresses the ISM and shocks and ionizes the region.

APA, Harvard, Vancouver, ISO, and other styles

10

Maloney, Philip. "Variability of Water Megamasers in AGN." Publications of the Astronomical Society of Australia 19, no. 1 (2002): 88–90. http://dx.doi.org/10.1071/as01106.

Full text

Abstract:

AbstractPowerful water masers have been detected in 23 active galactic nuclei (AGN) to date. Most of the sources that have been monitored show evidence for variability, which may be either intrinsic (response of the masers to a time-varying pump or background source) or extrinsic (the effects of scintillation in the interstellar medium of the Galaxy). I briefly review the examples in which these mechanisms may be operating (interstellar scintillation in the Circinus galaxy, a time-varying background source in Mrk 348, and a time-varying AGN luminosity in NGC 1068).

APA, Harvard, Vancouver, ISO, and other styles

11

Yang, Joseph Yuan-Mou, Richard Beare, Marc L. Seal, A. Simon Harvey, Vicki A. Anderson, and Wirginia J. Maixner. "A systematic evaluation of intraoperative white matter tract shift in pediatric epilepsy surgery using high-field MRI and probabilistic high angular resolution diffusion imaging tractography." Journal of Neurosurgery: Pediatrics 19, no. 5 (May 2017): 592–605. http://dx.doi.org/10.3171/2016.11.peds16312.

Full text

Abstract:

OBJECTIVECharacterization of intraoperative white matter tract (WMT) shift has the potential to compensate for neuronavigation inaccuracies using preoperative brain imaging. This study aimed to quantify and characterize intraoperative WMT shift from the global hemispheric to the regional tract-based scale and to investigate the impact of intraoperative factors (IOFs).METHODSHigh angular resolution diffusion imaging (HARDI) diffusion-weighted data were acquired over 5 consecutive perioperative time points (MR1 to MR5) in 16 epilepsy patients (8 male; mean age 9.8 years, range 3.8–15.8 years) using diagnostic and intraoperative 3-T MRI scanners. MR1 was the preoperative planning scan. MR2 was the first intraoperative scan acquired with the patient's head fixed in the surgical position. MR3 was the second intraoperative scan acquired following craniotomy and durotomy, prior to lesion resection. MR4 was the last intraoperative scan acquired following lesion resection, prior to wound closure. MR5 was a postoperative scan acquired at the 3-month follow-up visit. Ten association WMT/WMT segments and 1 projection WMT were generated via a probabilistic tractography algorithm from each MRI scan. Image registration was performed through pairwise MRI alignments using the skull segmentation. The MR1 and MR2 pairing represented the first surgical stage. The MR2 and MR3 pairing represented the second surgical stage. The MR3 and MR4 (or MR5) pairing represented the third surgical stage. The WMT shift was quantified by measuring displacements between a pair of WMT centerlines. Linear mixed-effects regression analyses were carried out for 6 IOFs: head rotation, craniotomy size, durotomy size, resected lesion volume, presence of brain edema, and CSF loss via ventricular penetration.RESULTSThe average WMT shift in the operative hemisphere was 2.37 mm (range 1.92–3.03 mm) during the first surgical stage, 2.19 mm (range 1.90–3.65 mm) during the second surgical stage, and 2.92 mm (range 2.19–4.32 mm) during the third surgical stage. Greater WMT shift occurred in the operative than the nonoperative hemisphere, in the WMTs adjacent to the surgical lesion rather than those remote to it, and in the superficial rather than the deep segment of the pyramidal tract. Durotomy size and resection size were significant, independent IOFs affecting WMT shift. The presence of brain edema was a marginally significant IOF. Craniotomy size, degree of head rotation, and ventricular penetration were not significant IOFs affecting WMT shift.CONCLUSIONSWMT shift occurs noticeably in tracts adjacent to the surgical lesions, and those motor tracts superficially placed in the operative hemisphere. Intraoperative probabilistic HARDI tractography following craniotomy, durotomy, and lesion resection may compensate for intraoperative WMT shift and improve neuronavigation accuracy.

APA, Harvard, Vancouver, ISO, and other styles

12

Castangia, P., G. Surcis, A. Tarchi, A. Caccianiga, P. Severgnini, and R. Della Ceca. "Water masers in Compton-thick AGN." Astronomy & Astrophysics 629 (August 29, 2019): A25. http://dx.doi.org/10.1051/0004-6361/201935421.

Full text

Abstract:

Aims. Investigations of H2O maser galaxies at X-ray energies reveal that most active galactic nuclei (AGN) associated with water masers are characterized by high levels of absorption. With the aim of finding new maser sources for possible interferometric follow-ups, we have searched for water maser emission in a well-defined sample of heavily absorbed AGN (NH > 1023 cm−2), including Compton-thick (CT) sources. Methods. Previous surveys already searched for 22 GHz water maser emission in all the galaxies in this sample. With the goal of providing a detection or a stringent upper limit on the H2O luminosity, we reobserved some of the non-detected sources with the Green Bank Telescope. A new luminous H2O maser (LH2O ∼ 200 L⊙) was detected in the mid-IR-bright Seyfert 2 galaxy IRAS 15480−0344 and then followed-up with the Very Long Baseline Array. In order to shed light on the origin of the maser (jet, outflow, or disk), we recently observed the radio continuum emission in IRAS 15480-0344 with the European VLBI network (EVN) at 1.7 and 5.0 GHz. Results. With the newly discovered megamaser in IRAS 15480−0344 revealing a narrow (∼0.6 km s−1) and a broad (∼90 km s−1) component, the maser detection rate of the CT AGN sample is 50% (18/36), which is one of the highest ever found in maser surveys. The EVN maps show two bright sources (labeled SW and NE) in the nuclear region of IRAS 15480−0344, which we interpret as jet knots tracing regions where the radio plasma impacts dense molecular clouds. The narrow maser feature is approximately at the center of the imaginary line connecting the two continuum sources, likely pinpointing the core, and might be associated with the accretion disk or a nuclear outflow. The location of the broad maser feature, instead, coincides with source NE, suggesting that the maser emission might be produced by a jet-cloud interaction, as it was proposed for NGC 1068 and Mrk 348.

APA, Harvard, Vancouver, ISO, and other styles

13

Josephi, Beate. "Beyond Journalism, Mark Deuze and Tamara Witschge (2020)." Australian Journalism Review 43, no. 1 (June 1, 2021): 149–50. http://dx.doi.org/10.1386/ajr_00068_5.

Full text

Abstract:

Review of: Beyond Journalism, Mark Deuze and Tamara Witschge (2020)Cambridge: Polity Press, 148 pp.,ISBN 978-0-74564-342-7, p/bk, $30.25ISBN 978-0-74564-341-0, h/bk, $57.00ISBN 978-0-74564-341-8, ebk, $26.99

APA, Harvard, Vancouver, ISO, and other styles

14

Malaspina, Francesco, Maria Caterina Putti, Michelina Santopietro, Saverio Ladogana, Rosamaria Mura, Roberta Burnelli, Nadia Vacca, et al. "Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome." Blood 132, Supplement 1 (November 29, 2018): 4256. http://dx.doi.org/10.1182/blood-2018-99-118030.

Full text

Abstract:

Abstract Imatinib mesylate (IM) has demonstrated to be highly effective in children with chronic myeloid leukemia (CML). The main issues remain the long-term side effects in pre-pubertal children and the poor compliance in adolescents. The aims of this study were: a) to evaluate the feasibility and efficacy of IM given intermittently to molecular responder (MR) CML children in chronic phase (CP), b) to reduce the long-term side effects of MR patients (pts) who started IM in pre-pubertal age, c) to improve compliance of poorly compliant adolescents in major MR (MMR). Among CP-CML pts aged <18 years at diagnosis treated with IM at a dose of 340 mg/m2/day and with a follow-up ≥36 months, those with a persistent MR4.5-MR5 or in MR with long-term side effects, and those in MMR who were poorly compliant to continuous IM, were considered eligible for an intermittent IM (int-IM) administration. The intermittent schedule consisted of IM administered at the same dose for 3 weeks monthly (3 weeks on, 1 week off). Quantitative molecular analysis of the BCR-ABL1 transcript levels was carried out monthly on peripheral blood and every 3 months on bone marrow, along with cytogenetics. Long-term side effects (bone and mineral metabolism, growth rate and pubertal development) were regularly monitored. Re-treatment with IM given continuously or with other tyrosine kinase inhibitors (TKI) was planned if there was a loss of MMR in two consecutive samples or a cytogenetic relapse. IM discontinuation was considered for patients with a persistent MR4.5-MR5. Fifteen of 58 CP-CML pts diagnosed between March 2001 and June 2015 received IM given intermittently for a median of 40 months(range: 14-86). Before starting int-IM, 5 pts had been in persistent MR4.5-MR5 for a median of 39 months (Group I), 4 pts had been in MR for a median of 28.5 months and had been suffering from long-term side effects (Group II), and 6 pts had been in MMR and were poorly compliant to treatment (Group III). Features and outcome of the 15 pts are shown in Table 1. Group I: 3/5 pts in MR4.5-MR5 discontinued int-IM after 16, 34 and 36 months and remain in continuous MR after 89, 90 and 107 months; 2 pts are still receiving int-IM for 14 and 36 months, respectively. Group II: 2/4 pts achieved a deeper MR (1 from MR4 to MR4.5 and 1 from MR4.5 to MR5) while on int-IM. However, 3 pts lost the response after 24 (cytogenetic relapse), 40 and 77 (molecular) months from the beginning of int-IM; all of them were successfully treated with IM given continuously. One pt is still receiving int-IM. Group III: 2/6 pts achieved a deeper MR (1 from MR3 to MR4.5 and 1 from MR3 to MR4) while on int-IM. However, 5/6 patients lost their response after a median time of 69 months (57-74). Four of them were treated with IM given continuously and 1 received dasatinib; all obtained a response. One, who achieved a deeper MR (MR3 to MR4), is still on int-IM after 86 months. Overall, 4/15 (26.7%) pts improved their molecular response while on int-IM and 3/15 pts (20%) successfully discontinued treatment. On the other hand, 8/15 pts (53.3%) failed int-IM after a median of 63 months (range 24-77) from the beginning (6 pts lost MMR and 2 pts had a cytogenetic relapse). No pt underwent a stem cell transplantation. Long-term side effects (bone metabolism, growth rate and pubertal development) progressively improved during IM given intermittently. At the last follow-up, 6 pts (4 MR5, 1 MR4.5, 1 MR3) are still receiving int-IM, 5 (3 MR4, 2 MR2) are receiving continuous IM, 3 (MR4.5-MR5) are treatment-free and 1 (MR3) is being treated with dasatinib. All patients are alive at a median time from diagnosis of 151 months (range 52-266). Our experience suggests that an intermittent schedule of IM given 3 weeks a month could be an effective strategy before stopping IM in CP-CML children in persistent deep MR. Moreover, this approach is capable of improving the molecular response in poor compliant pts and is useful to reduce IM-related long-term side effects. The relatively high number of relapses in group III (5/6, 83%) is indicative of its poor efficacy in pts not compliant to IM given continuously. Based on these data, a prospective cooperative study has been planned. Disclosures Malaspina: Sapienza University, Rome: Other: Resident in Hematology. Rizzo:Sapienza University, Rome: Other: Resident in Hematology. Locatelli:bluebird bio: Consultancy; Bellicum: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Foà:CELGENE: Other: ADVISORY BOARD, Speakers Bureau; AMGEN: Other: ADVISORY BOARD; CELTRION: Other: ADVISORY BOARD; GILEAD: Speakers Bureau; NOVARTIS: Speakers Bureau; JANSSEN: Other: ADVISORY BOARD, Speakers Bureau; INCYTE: Other: ADVISORY BOARD; ABBVIE: Other: ADVISORY BOARD, Speakers Bureau; ROCHE: Other: ADVISORY BOARD, Speakers Bureau.

APA, Harvard, Vancouver, ISO, and other styles

15

Diaz, B., D. Barnard, A. Filson, S. MacDonald, A. King, and M. Marshall. "Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling." Molecular and Cellular Biology 17, no. 8 (August 1997): 4509–16. http://dx.doi.org/10.1128/mcb.17.8.4509.

Full text

Abstract:

Activation of the Raf serine/threonine protein kinases is tightly regulated by multiple phosphorylation events. Phosphorylation of either tyrosine 340 or 341 in the catalytic domain of Raf-1 has been previously shown to induce the ability of the protein kinase to phosphorylate MEK. By using a combination of mitogenic and enzymatic assays, we found that phosphorylation of the adjacent residue, serine 338, and, to a lesser extent, serine 339 is essential for the biological and enzymatic activities of Raf-1. Replacement of S338 with alanine blocked the ability of prenylated Raf-CX to transform Rat-1 fibroblasts. Similarly, the loss of S338-S339 in Raf-1 prevented protein kinase activation in COS-7 cells by either oncogenic Ras[V12] or v-Src. Consistent with phosphorylation of S338-S339, acidic amino acid substitutions of these residues partially restored transforming activity to Raf-CX, as well as kinase activation of Raf-1 by Ras[V12] or v-Src. Two-dimensional phosphopeptide mapping of wild-type Raf-CX and Raf-CX[A338A339] confirmed the presence of a phosphoserine-containing peptide with the predicted mobility in the wild-type protein which was absent from the mutant. This peptide could be quantitatively precipitated by an antipeptide antibody specific for the 18-residue tryptic peptide containing S338-S339 and was demonstrated to contain only phosphoserine. Phosphorylation of this peptide in Raf-1 was significantly increased by coexpression with Ras[V12]. These data demonstrate that Raf-1 residues 338 to 341 constitute a unique phosphoregulatory site in which the phosphorylation of serine and tyrosine residues contributes to the regulation of Raf by Ras, Src, and Ras-independent membrane localization.

APA, Harvard, Vancouver, ISO, and other styles

16

KATAKAMI, Eishi, Nobuaki TAKAGI, Takao YAKOU, Mayumi NAKATA, and Keijirou YAMAMOTO. "348 The proposal of a woody sign as the land mark." Proceedings of the Dynamics & Design Conference 2004 (2004): _348–1_—_348–4_. http://dx.doi.org/10.1299/jsmedmc.2004._348-1_.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Specchia, Giorgina, Patrizia Pregno, Maura Nicolosi, Fausto Castagnetti, Bruno Martino, Massimo Breccia, Massimiliano Bonifacio, et al. "Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group." Blood 132, Supplement 1 (November 29, 2018): 45. http://dx.doi.org/10.1182/blood-2018-99-116648.

Full text

Abstract:

Abstract Background: The advent of Tyrosine Kinase Inhibitors (TKI) totally changed the outcome of patients affected by Chronic Myeloid Leukemia (CML). Most of informations about the clinical characteristics of CML patients are based on data derived from clinical trials, that often exclude patients not fitting with strict inclusion criteria. In real life may be important to know the characteristics of the entire CML patients' population and this is better reflected by registries studies including all consecutive patients. Aim: To provide a robust and updated information on clinical, hematologic characteristics and treatment response in non-selected Italian patients with CML in each phase of the disease. Methods:We retrospectively and prospectively recorder in a web-based database clinical, hematological, cytogenetic and biological informations about all new diagnosis of CML patients referred to Italian Hematology Centers of the GIMEMA Study Group from January 2012 to June 2016. Results:Our study covered 1051 patients newly diagnosed with CML and treated between January 2012 and June 2016 in 66 Italian centers. Median age at diagnosis was 59 years (range 47-71) and 60.8% were males. At diagnosis among 908 patients 899 (99%) patients were in chronic phase, 7 (0.8%) patients in accelerate phase and 2 (0.2%) in blastic crisis. Among 1051 patients, 148 (14%), 351 (33%), 318 (30.3%) were high, intermediate and low risk by Sokal with 234 (22.2%) missing; 54 (5%), 418 (40%), 342 (32.5%) high, intermediate and low risk by EURO with 237 (22.6%) missing; 55 (5%) and 797 (76%) high and low risk by EUTOS with 199 (18.9%) missing; 96 (9%), 208 (20%), 533 (51%) high, intermediate and low risk by ELTS with 214 (20.4%) missing, respectively. The median follow-up was 36 months and 36 patients died (10 CML related). At cytogenetic analysis, there were 887 available informations: 809 (77%) without additional cytogenetic aberrations (ACA), 49 (5%) with major route and 29 (2.8%) with minor route ACA respectively. BCR-ABL transcripts among 873 data available were: b2a2 in 303 (34.7%), b3a2 in 493 (56.5%), b2a2+b3a2 in 61 (7%), e1a2 in 12 (1.4%), e19a2 in 2 (0.2%) b3a2+e1a2 in 2 (0.2%) patients respectively. ECOG performance status among 801 patients was 0, 1, or ≥ 2 in 585 (73%), 181 (22.6%) and 35 (4.4%) cases respectively. According to co-morbidity and excluding CML diagnosis as parameter, among 995 cases the Charlson comorbidity index, was 0, 1, 2 or ≥3 in 771 (73.4%), 115 (11%), 60 (5.7%) and 49 (4.7%) patients respectively; among 556 patients cardiovascular, lung, metabolic and oncologic diseases were observed in 283 (24%), 108 (10.3%), 77 (7.3%) and 88 (8.4%) patients respectively. Five hundred-ten (48.5%) and 541 (51.4%) patients were treated in first-line with imatinib (IMA) and with II generation TKI (IIGen-TKI) respectively. Three hundred twenty-one (30%) cases were pretreated with hydroxyurea. Molecular responses data at 3th month were available in 728 patients and of these 102 (14.01%) obtained at least Major Molecular Response IS (MR) MR3, 29 (3.98%) MR4, 27 (3.71%) MR4.5, 13 (1.79%) MR5 and 11 (1.5%) undetectable BCR-ABL1transcript, respectively. At 6thmonth, among 731 data available, at least 292 patients (39,57%) obtained MR3, 90 (12,19%) MR4, 75(10.16%) MR4.5, 35 (4.74%) MR5 and 29 (3.97%) undetectable BCR-ABL1transcript, respectively. At 12thmonth among 709 molecular responses available, 425 patients (59.94%) achieved at least MR3, 203 (28,63%) MR4, 171 (24.12%) MR4.5, 90 (12.69%) MR5 and 78 (11%) undetectable BCR-ABL1transcript, respectively. As showed in table 1, the IIGen-TKI were able to obtain a higher, earlier and deeper molecular response at 3th, 6thand 12thmonth than IMA. Data analysis about responses at 24thmonth are ongoing. Overall survival at 5 years was 93.4% (95% IC 90.1-95.6). Conclusions:Our preliminary results of this observational epidemiologic study suggest that collection of clinical data of CML patients treated out of strictly clinical trials represent an essential tool for long/term treatment, able to observe setting strategies based on the clinical characteristics, the degree of response obtained, and the toxicity related to the therapy in overall CML population. We are planning to continue to analyze all these endpoints to estimate the response and toxicity according to ELN guidelines, and feasibility of treatment sequence in a cohort of patients treated in real-life. Disclosures Castagnetti: Pfizer: Consultancy, Honoraria; Bristol Meyers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Breccia:BMS: Honoraria; Incyte: Honoraria; Pfizer: Honoraria; Novartis: Honoraria. Pane:AMGEN: Speakers Bureau; Novartis: Research Funding, Speakers Bureau; BMS: Speakers Bureau.

APA, Harvard, Vancouver, ISO, and other styles

18

Kung, Charles, Collin Hill, Yue Chen, Abhishek Jha, Penelope Kosinski, Michelle Clasquin, Yaguang Si, et al. "AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice." Blood 124, no. 21 (December 6, 2014): 4010. http://dx.doi.org/10.1182/blood.v124.21.4010.4010.

Full text

Abstract:

Abstract Pyruvate kinase deficiency (PKD) is an autosomal recessive enzymopathy that is the most common cause of hereditary nonspherocytic hemolytic anemia (HNSHA). PKD is a rare disease characterized by a life-long chronic hemolysis with severe co-morbidities. It is hypothesized that insufficient energy production to maintain red cell membrane homeostasis promotes the chronic hemolysis. Treatment is generally palliative, focusing on the resultant anemia, and there are no approved drugs that directly target mutated pyruvate kinase. AG-348 is an allosteric activator of the red cell isoform of pyruvate kinase (PKR) that has recently entered Phase I clinical trials in normal healthy volunteers. AG-348 increases the catalytic efficiency and enhances the protein stability of a spectrum of recombinantly expressed PKR mutant proteins that have been associated with PKD. PKD red cells are characterized by changes in metabolism associated with defective glycolysis, including a build-up of the upstream glycolytic intermediate 2,3-DPG and deficiency in the PKR product adenosine triphosphate (ATP). PKR flux, e.g. the rate of carbon flow through the PKR enzyme reaction, was examined in PKD patient or wild type (WT) donor blood samples by incubation of whole blood with a stable isotope tracer, [U-13C6]-glucose. At various time points after the addition of [U-13C6]-glucose, metabolism was quenched and metabolites were extracted. Metabolite pool sizes and 13C label incorporation into glycolytic intermediates were monitored by LC/MS. The rate of label incorporation was found to be significantly slower in PKD patient red cells, consistent with decreased glycolytic activity. Treatment of PKD red cells with AG-348 ex-vivo induces changes in metabolism consistent with increased glycolytic activity including reduced 2,3-DPG levels, increased ATP levels, and increased PKR enzyme activity levels. The effect of AG-348 on red cell metabolism in vivo was evaluated in mice. C57/BL6 mice were dosed by oral gavage either with a single dose, or with multiple doses (BID) of AG-348 for 7 days. Dose levels tested were 1 mpk, 10 mpk, 50 mpk, and 150 mpk. Following the last dose, mice were bled to evaluate drug exposure and pharmacodynamic markers including 2,3-DPG and ATP levels, and PKR activity. AG-348 was demonstrated to be a well-behaved compound, with dose-proportional increase in exposure, both in the single-dose and multiple dose studies. A single dose of AG-348 resulted in a dose-dependent increase in PKR activity levels, concomitant with reduction in 2,3-DPG levels. There were no significant changes in ATP levels after a single administration of AG-348. In the multiple-dose studies, similar changes in PKR activity and 2,3-DPG levels were observed. In contrast to the single-dose study, ATP levels were observed to be robustly increased in a dose-dependent manner. The effect of AG-348 on PKR flux was assessed in whole blood from mice treated with AG-348. C57BL/6 mice were dosed by oral gavage with AG-348 (150 mg/kg twice daily [BID]) for 3 days. Whole blood was incubated with [U-13C6]-glucose and the metabolite pool sizes and rate of 13C label incorporation into glycolytic intermediates were assessed. The data were subsequently analyzed using a mathematical model to quantify flux through the PKR reaction and it was determined that AG-348 treatment significantly increased flux through the PKR reaction. Collectively, these data demonstrate that AG-348 not only potently binds to and activates the PKR enzyme in vivo, but this enzyme activation induces enhanced glycolytic pathway activity in red cells that results in profound changes in cellular metabolism, as reflected in dramatically increased ATP levels and reduced 2,3-DPG levels. As AG-348 has similar potency against the WT PKR enzyme as against tested mutant PKR enzymes in vitro, these data support the hypothesis that AG-348 treatment may similarly enhance glycolytic activity in PKD patients and thus correct the underlying pathology of PKD. Figure 1 Figure 1. Disclosures Kung: Agios Pharmaceuticals: Employment, Stockholder Other. Hill:Agios Pharmaceuticals: Employment, Stockholder Other. Chen:Agios Pharmaceuticals: Employment, Stockholder Other. Jha:Agios Pharmaceuticals: Employment, Stockholder Other. Kosinski:Agios Pharmaceuticals: Employment, Stockholder Other. Clasquin:Agios Pharmaceuticals: Employment, Stockholder Other. Si:Agios Pharmaceuticals: Employment, Stockholder Other. Kim:Agios Pharmaceuticals: Employment, Stockholder Other. Hixon:Agios Pharmaceuticals: Employment, Stockholder Other. Dang:A: Employment, Stockholder Other. Agresta:Agios Pharmaceuticals: Employment, Stockholder Other. Silverman:Agios Pharmaceuticals: Employment, Stockholder Other. Yang:Agios Pharmaceuticals: Employment, Stockholder Other.

APA, Harvard, Vancouver, ISO, and other styles

19

Gawęda, Aleksandra, Krzysztof Szopa, and David Chew. "LA-ICP-MS U-Pb dating and REE patterns of apatite from the Tatra Mountains, Poland as a monitor of the regional tectonomagmatic activity." Geochronometria 41, no. 4 (December 1, 2014): 306–14. http://dx.doi.org/10.2478/s13386-013-0171-0.

Full text

Abstract:

Abstract This study presents apatite LA-ICP-MS U-Pb age and trace elements concentrations data from different granite types from the Tatra Mountains, Poland. Apatite from monazite and xenotime-bearing High Tatra granite was dated at 339 ± 5 Ma. The apatite LREE patterns reflect two types of magmas that contributed to this layered magma series. Apatite from a hybrid allanite-bearing diorite from the Goryczkowa Unit was dated at 340 ± 4 Ma with apatite LREE depletion reflecting the role of allanite and titanite during apatite crystallization. Apatite crystals from a hybrid cumulative rock from the Western Tatra Mountains were dated at 344 ± 3 Ma. Apatite is one of the main REE carriers in this sample and exhibit flat REE patterns. Taking into account the relatively low closure temperature of the U-Pb system in apatite (350–550°C), the c. 340 Ma apatite ages mark the end of high temperature tectonometamorphic activity in the Tatra Mountains.

APA, Harvard, Vancouver, ISO, and other styles

20

Kim, ChangJoo. "An Eclipse of ‘Great Cry’: Mark 15:34." Theological Studies 79 (December 31, 2021): 83–105. http://dx.doi.org/10.46334/ts.2021.12.79.83.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kawasaki, Shinji, Hiroshi Nishimura, and Junichi Taguchi. "342. Development of double slice acquisition method with 0.2T MRI system." Japanese Journal of Radiological Technology 48, no. 8 (1992): 1425. http://dx.doi.org/10.6009/jjrt.kj00003500738.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Claudiani, Simone, Silvia Metelli, Rafiee Kamvar, Richard Szydlo, Afzal Khan, Jenny Byrne, Paolo Gallipoli, et al. "Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)." Blood 134, Supplement_1 (November 13, 2019): 26. http://dx.doi.org/10.1182/blood-2019-131500.

Full text

Abstract:

Background: Treatment free remission (TFR) is now a realistic goal of treatment for CML. Approximately 50% of patients (pts) who discontinue tyrosine kinase inhibitors (TKI) after achieving deep molecular responses (DMR) are able to remain off treatment without losing major molecular response (MR3). Data from the largest available TKI stopping trial, EURO-SKI, showed that the most important variable associated with prolonged TFR is the duration of DMR. However, to date no clinical tool exists to guide clinicians and patients in predicting the likelihood of success of TFR attempt. Methods: We performed a retrospective analysis of clinical data from 172 pts with CML in whom treatment was discontinued in 6 hospital centres in order to identify factors associated with TFR. Data analysis started with a training set (TS) derived from pts treated at a single centre which was then validated on a validation set (VS) derived from the 5 other centres. Eligibility criteria included diagnosis of CML in chronic phase, a minimum duration of treatment with TKI of 3 years and discontinuation of TKI after achievement of confirmed ≥MR4. Patients diagnosed in accelerated phase CML and/or who underwent prior allogeneic stem cell transplant were excluded. Kaplan-Meier method was used for univariate analysis, with log-rank test for group comparison. A Cox proportional hazards model was employed with the purpose of choosing the most influential prognostic predictors on the probability of TFR in MR3 (pTFR3) and TFR in MR4 (pTFR4) on the TS. Variables with a p-value ≤0.1 entered in the multivariate analysis (MVA). Proportional hazard assumptions were tested for the final model. A prognostic TFR score was built from the combination of the predictors identified by the Cox model and validated on the VS. Results: The TS included 118 pts, while the VS 54 pts (Table 1). In the TS, the 2-year pTFR3 was 67.4% (95% CI 66.5-68.3%) and the 2-y pTFR4 was 56.8% (95% CI, 55.9-57.7%). The median time to MR3 loss was 3.8 months (range 1-31), and for MR4 loss was 3.2 months (range 0.8-24.5). After loss of MR4, the 1-year probability of MR3 loss was 77% (95% CI, 70.8-73.2%). However, 10 pts (8.5%) resumed TKI after MR4 loss and were not evaluable for time to loss of MR3. In univariate analysis, the variables most significantly associated with higher pTFR3 and pTFR4 were age at diagnosis >40 years (p=0.029 and p=0.002), absence of previous TKI resistance (p=0.003 and p= 0.068), longer duration of MR4 (p=0.003 and p<0.0001) and ≥MR4.5 at stopping (p=0.026 and p= 0.004). Variables entered into the MVA were age at diagnosis, BCR-ABL1 transcript type, Sokal score, dose of TKI at stopping, previous TKI resistance, duration of MR4 at stopping, depth of response at stopping. The Cox model suggested the inclusion of the following variables, for both pTFR3 and pTFR4: duration of MR4, previous TKI resistance, age at diagnosis and transcript type. Using these variables we developed a predictive score (Figure 1a), which was able to identify a good risk population (2-y pTFR3 81.8%, 2-y pTFR4 80%); intermediate (66.6% and 61.5%) and poor risk (42.3% and 30.8%) (overall log-rank test p=0.00092 and p <0.0001 for pTFR3 and pTFR4, respectively)(Figure 1b). The score was tested on the VS of 54 pts. In this population, the overall 2-y pTFR3 and pTFR4 were 61.3% (95% CI, 59.8-62.7%) and 42.6% (95% CI, 41.2-44%), respectively. Despite the small sample size, our score was still able to predict different 2-y TFR probabilities (Figure 1c) in the three risk groups. Of the pts who lost MR3 in the TS (n=39), 37 regained ≥MR3 after resuming TKI; 1 patient did not restart TKI and died from an unrelated cause; 1 patient had only 2 months follow-up after TKI resumption. In the VS, 15 of 21 pts losing MR3 achieved ≥MR3 again after TKI resumption; 3 pts had a follow-up <3 months after MR3 loss, 2 were lost to follow-up and 1 had not yet re-gained MR3 6 months after restarting TKI. In both cohorts no case of disease progression had occurred at last follow-up. Conclusions:This retrospective study confirms the safety of TFR attempt and identifies variables strongly associated with prolonged TFR. The resulting predictive score presented here, if validated in larger patient cohorts, might help in tailoring the choice of TKI discontinuation to the individual patient. Also, most pts who lose MR4 inevitably lose MR3, suggesting the importance of a more intense monitoring strategy in this subgroup. Disclosures Claudiani: Pfizer: Honoraria; Incyte: Honoraria. Byrne:Ariad/Incyte: Honoraria, Speakers Bureau. Rothwell:Incyte: Speakers Bureau; Novartis: Honoraria, Other: advisory board; Pfizer: Speakers Bureau. Copland:Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Honoraria, Speakers Bureau; Cyclacel: Research Funding; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Clark:Ariad/Incyte: Honoraria; Pfizer: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Milojkovic:BMS: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau. Apperley:Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

APA, Harvard, Vancouver, ISO, and other styles

23

Lassen, Augusto E., Rogerio Riffel, Ana L. Chies-Santos, Evelyn Johnston, Boris Häußler, Gabriel M. Azevedo, Daniel Ruschel-Dutra, and Rogemar A. Riffel. "The metal-poor dwarf irregular galaxy candidate next to Mrk 1172." Monthly Notices of the Royal Astronomical Society 506, no. 3 (July 1, 2021): 3527–39. http://dx.doi.org/10.1093/mnras/stab1838.

Full text

Abstract:

ABSTRACT In this work, we characterize the properties of the object SDSS J020536.84−081424.7, an extended nebular region with projected extension of 14 × 14 kpc2 in the line of sight of the ETG Mrk 1172, using unprecedented spectroscopic data from MUSE. We perform a spatially resolved stellar population synthesis and estimate the stellar mass for both Mrk 1172 (1 × 1011 M⊙) and our object of study (3 × 109 M⊙). While the stellar content of Mrk 1172 is dominated by an old (∼10 Gyr) stellar population, the extended nebular emission has its light dominated by young to intermediate age populations (from ∼100 Myr to ∼1 Gyr) and presents strong emission lines such as H β; [O iii] λλ4959, 5007 Å; H α; [N ii] λλ6549, 6585 Å; and [S ii] λλ6717, 6732 Å. Using these emission lines, we find that it is metal poor (with Z ∼ 1/3 Z⊙, comparable to the LMC) and is actively forming stars (0.70 M⊙ yr−1), especially in a few bright clumpy knots that are readily visible in H α. The object has an ionized gas mass ≥3.8 × 105 M⊙. Moreover, the motion of the gas is well described by a gas in circular orbit in the plane of a disc and is being affected by interaction wtih Mrk 1172. We conclude that SDSS J020536.84−081424.7 is most likely a dwarf irregular galaxy (the dIGal).

APA, Harvard, Vancouver, ISO, and other styles

24

Mukai, takayuki, kuniomi Fujita, takao Asaka, askitsugu Iwasaki, and tateo Korenaga. "308 3D-FISP MRI of knee joint." Japanese Journal of Radiological Technology 51, no. 10 (1995): 1379. http://dx.doi.org/10.6009/jjrt.kj00001353080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ishii, H., N. Sunohara, M. Tanaka, and N. Nakamura. "328. Evaluation of breast tumor by MRi using of Gd-DTPA and subtraction imaging." Japanese Journal of Radiological Technology 48, no. 8 (1992): 1411. http://dx.doi.org/10.6009/jjrt.kj00003500724.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Horigoshi, Michihiro, Makoto Saitoh, and Shigeru Kikuchi. "378. Trial of MRI-diagnosis for the depth invasion of gastric cancer." Japanese Journal of Radiological Technology 49, no. 8 (1993): 1401. http://dx.doi.org/10.6009/jjrt.kj00003324964.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Turner, Robert. "Magnetic resonance imaging techniques ajay m. parikh. elsevier, new york, 1992. 349 pp." Magnetic Resonance in Medicine 27, no. 2 (October 1992): 398–99. http://dx.doi.org/10.1002/mrm.1910270222.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Shainyan, Bagrat A., Mikhail Yu Moskalik, Matthias Heydenreich, and Erich Kleinpeter. "Conformational equilibrium and dynamic behavior of bis-N -triflyl substituted 3,8-diazabicyclo[3.2.1]octane." Magnetic Resonance in Chemistry 52, no. 8 (June 10, 2014): 448–52. http://dx.doi.org/10.1002/mrc.4086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Ilyasa, Himawan Tri, Suhariyanto Suhariyanto, and Wahiddin Wahiddin. "PERENCANAAN ACUAN DAN PERANCAH PADA PROYEK PEMBANGUNAN JAKARTA INTERNATIONAL STADIUM JAKARTA UTARA." Jurnal JOS-MRK 2, no. 4 (December 15, 2021): 290–94. http://dx.doi.org/10.55404/jos-mrk.2021.02.04.290-294.

Full text

Abstract:

Jakarta International Stadium Jakarta Utara merupakan Stadion mempunyai standarisasi berskala international dengan kapasitas 82.000 penonton dan berjumlah 9 lantai, pelaksanaan pekerjaan bekisting merupakan salah satu komponen pekerjaan struktur yang membutuhkan biaya cukup besar. Permasalahan dari perencanaan menentukan desain bekisting yang akan direncanakan. Tujuan dari perencanaan meliputi penentuan strategi, metode pelaksanaan, perhitungan biaya, penjadwalan, dan Analisa Keselamatan, kesehatan kerja dan lingkungan. Dalam Menyusun penjadwalan memakai software Ms. Project. Perhitungan biaya proyek, daftar harga, bahan, dan upah tenaga kerja menggunakan daftar harga Kota Jakarta Utara 2020. Berdasarkan hasil perhitungan didapat total biaya pekerjaan struktur pembangunan Jakarta International Stadium pada Zona 3B dan Zona 4B, Jakarta Utara, Provinsi DKI Jakarta sebesar Rp 5.764.910.018,- dengan waktu penyelesaian 308 hari

APA, Harvard, Vancouver, ISO, and other styles

30

Nunes, F. M., B. A. Barros-Filho, M. C. F. de Oliveira, M. Andrade-Neto, M. C. de Mattos, J. Mafezoli, and J. R. Pirani. "1H and13C NMR spectra of 3,8-dimethoxyfuro[3,2-g]coumarin and maculine fromEsenbeckia grandiflora Martius (Rutaceae)." Magnetic Resonance in Chemistry 43, no. 10 (2005): 864–66. http://dx.doi.org/10.1002/mrc.1621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Shimada, Tetsuo, Yoko Takizawa, Keiko Endo, Kiyomi Ooi, Tadao Terai, Yoshitaka Nishimura, and Masaki Ookubo. "308. Improved T1 Contrast Images with 1/2 Scan Time ECG Gating." Japanese Journal of Radiological Technology 50, no. 8 (1994): 1224. http://dx.doi.org/10.6009/jjrt.kj00003326108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Worthington, Brian S. "Magnetic resonance annual 1988, edited by Herbert Y. Kressel. Raven Press, New York. 1988. 346 pp. $69.50." Magnetic Resonance in Medicine 7, no. 3 (July 1988): 371. http://dx.doi.org/10.1002/mrm.1910070316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Doğan, Özlem. "KONAKLAMA İŞLETMELERİNDE KAR PLANLAMASI ARACI OLARAK MHK ANALİZLERİNİN BULANIK M." Journal of Social Sciences 11, no. 11 (January 1, 2017): 1–10. http://dx.doi.org/10.16990/sobider.3484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Stuckey, Peter J. "Constraint Logic Programming using ECLiPSeKrzysztof Apt and Mark Wallace Cambridge University Press, 2007 Hardback: ISBN 9780521866286, Price: £35, 348 pages." Theory and Practice of Logic Programming 8, no. 2 (March 2008): 242–46. http://dx.doi.org/10.1017/s1471068408003281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Jeannerat, D. "C. Schorn. NMR spectroscopy: data acquisition. Wiley-VCH, Weinheim, 2001, 347 pp. Price £95. ISBN 3 527 28827 9." Magnetic Resonance in Chemistry 41, no. 4 (March 5, 2003): 304. http://dx.doi.org/10.1002/mrc.1166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Li, Chang, Yuning Zhou, Heidi L. Weiss, Qingding Wang, and B. Mark Evers. "349: POST-TRANSCRIPTIONAL REGULATION OF OCCLUDIN BY MEK/OXPHOS SIGNALING IN INTESTINAL CELLS." Gastroenterology 162, no. 7 (May 2022): S—75. http://dx.doi.org/10.1016/s0016-5085(22)60189-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Zahroh, Fatimatuz. "ETIKA PROFETIK CERPEN “NASIHAT KIAI LUQNI”, “HILANGNYA PERANGKAT DESA”, “KANG MAKSUM”, DAN “NYAI SOBIR” KARYA AHMAD MUSTOFA BISRI." CARAKA 8, no. 1 (December 2, 2021): 169–84. http://dx.doi.org/10.30738/ca.v8i1.10221.

Full text

Abstract:

Penelitian ini bertujuan mendeskripsikan etika humanisasi, etika liberasi, etika transendensi dalam cerpen â€œNasihat Kiai Luqniâ€, â€œHilangnya Perangkat Desaâ€, â€œKang Maksumâ€, dan â€œNyai Sobirâ€ Karya A. Mustofa Bisri, serta penerapan nilai-nilai profetik dalam pembelajaran kelas XI SMA/SMK/MA/MAK pada KD 3.8 dan 4.8. Penelitian ini menggunakan metode kualitatif. Metode pengumpulan data menggunakan metode kualitatif dan teknik baca dan catat. Metode analisis data menggunakan metode kualitatif dan teknik deskriptif kualitatif. Hasil penelitian menunjukkan bahwa di dalam cerpen â€œNasihat Kiai Luqniâ€, â€œHilangnya Perangkat Desaâ€, â€œKang Maksumâ€, dan â€œNyai Sobirâ€ karya A. Mustofa Bisri terdapat nilai-nilai profetik yang dapat diterapkan dalam pembelajaran Bahasa Indonesia di kelas XI SMA/SMK/MA/MAK pada KD 3.8 dan 4.8. Nilai-nilai profetik tersebut diantaranya : nilai religius, tanggung jawab, toleransi, mandiri, demokratis, dan jujur.

APA, Harvard, Vancouver, ISO, and other styles

38

Byrne, Lauren M., Eric S. Holmboe, John R. Combes, and Thomas J. Nasca. "From Medical School to Residency: Transitions During the COVID-19 Pandemic." Journal of Graduate Medical Education 12, no. 4 (August 1, 2020): 507–11. http://dx.doi.org/10.4300/jgme-d-20-00627.1.

Full text

Abstract:

ABSTRACT Background The start of a new academic year in graduate medical education will mark a transition for postgraduate year 1 (PGY-1) residents from medical school into residency. The relocation of individuals has significant implications given the COVID-19 pandemic and variability of the outbreak across the United States, but little is known about the extent of the geographic relocation taking place. Objective We reported historical trends of PGY-1 residents staying in-state and those starting residency from out-of-state to quantify the geographic movement of individuals beginning residency training each year. Methods We analyzed historical data collected by the Accreditation Council for Graduate Medical Education in academic years 2016–2017, 2017–2018, and 2018–2019, comparing the locations of medical school and residency programs for PGY-1 residents to determine the number of matriculants from in-state medical schools and out-of-state medical schools. International medical school graduates (IMGs) were shown separately in the analysis and then combined with out-of-state matriculants. US citizens who trained abroad were counted among IMGs. Results The total number of PGY-1s increased by 10.3% during the 3-year time period, from 29 338 to 32 348. When combined, IMGs and USMGs transitioning from one state or country to another state accounted for approximately 72% of PGY-1s each year. Approximately 63% of USMGs matriculated to a residency program in a new state, and IMGs made up 24.6% to 23.1% of PGY-1s over the 3-year period. Conclusions Each year brings a substantial amount of movement among PGY-1s that highlights the need for policies and procedures specific to the COVID-19 pandemic.

APA, Harvard, Vancouver, ISO, and other styles

39

Clinton, Eshter. "Titus Hjelm, Keith Kahn-Harris & Mark LeVine (eds.), “Heavy metal : controversies." Volume !, no. 9 : 2 (December 15, 2012): 233–35. http://dx.doi.org/10.4000/volume.3481.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Chen, Changmin, and Arthur J. Sytkowski. "Erythropoietin regulation of Raf-1 and MEK: evidence for a Ras-independent mechanism." Blood 104, no. 1 (July 1, 2004): 73–80. http://dx.doi.org/10.1182/blood-2003-04-1340.

Full text

Abstract:

Abstract Stimulation of the erythropoietin (EPO) receptor triggers a cascade of signaling events. We reported that EPO upregulates c-myc expression through 2 pathways in BaF3-EpoR cells—a phosphatidylinositol 3-kinase (PI3K) pathway operating on transcriptional initiation and a Raf-1–mitogen-activated protein kinase (MAPK) pathway affecting elongation. We now show that EPO induces phosphorylation of Raf-1 at serine 338 and within the carboxy-terminal domain, resulting in an electrophoretic mobility change (hyperphosphorylation). Importantly, MEK 1 inhibitor PD98059 blocked only the hyperphosphorylation of Raf-1 but not the phosphorylation at serine 338. This inhibition of Raf-1 hyperphosphorylation resulted in increased kinase activity of Raf-1 and increased phosphorylation of MEK, suggesting that the hyperphosphorylation of Raf-1 inhibits its MEK kinase activity. Deletion of the first 184 amino acids of Raf-1, which are involved in its interaction with Ras, had no effect on EPO-induced phosphorylation. Introducing the dominant-negative N17Ras or GAP had no effect on EPO-induced kinase activity of Raf-1 and ELK activation. N17Ras failed to inhibit ELK activation in another cell line—Rauscher murine erythroleukemia— which expresses the EPO receptor endogenously and differentiates in response to the hormone. These results indicate the presence of a Ras-independent mechanism for Raf-1 and MEK activation in these cells.

APA, Harvard, Vancouver, ISO, and other styles

41

Wang, Shichun, Qianqian Tang, Fuchao Ge, and Qing Guo. "Typhae pollen polysaccharides protect hypoxia-induced PC12 cell injury via regulation of miR-34a/SIRT1." International Journal of Immunopathology and Pharmacology 34 (January 2020): 205873842091000. http://dx.doi.org/10.1177/2058738420910005.

Full text

Abstract:

This current research was performed to investigate the role of typhae pollen polysaccharides (TPP) in hypoxia-treated PC12 cell which was an in vitro cell model of cerebral ischemia. Hypoxia-treated cells were treated with TPP for 12 h. Cell viability and apoptosis were detected by 3-(4,5-dimethylthiazol-2-yl)-2 5-diphenyl-2H-tetrazolium bromide (MTT) assay and flow cytometry, respectively. Cell apoptotic proteins and PI3K/AKT and Ras/Raf/MEK/ERK signal pathway–associated proteins were also examined by western blot. Furthermore, abnormal expression of miR-34a and silent information regulator 1 (SIRT1) was achieved by transfection. Besides, the expression of miR-34a and SIRT1 was examined by quantitative real-time polymerase chain reaction (qRT-PCR). The expression of SIRT1 was detected by qRT-PCR and western blot. The relationship between miR-34a and SIRT1 was verified by luciferase assay. We found that TPP enhanced cell viability and inhibited apoptosis in hypoxia-treated PC12 cells. Moreover, TPP increased the accumulated levels of Bcl-2 while decreased expression of Bax, cleaved Caspase-3, and cleaved PARP. TPP downregulated miR-34a expression while induced by hypoxia. Further results showed that miR-34a overexpression reversed the results led by TPP in cell viability, apoptosis, and its related proteins. In addition, SIRT1 was upregulated by TPP and was verified to be a target of miR-34a. Silence of SIRT1 led to the opposite results led by TPP. In the end, TPP activated PI3K/AKT and Ras/Raf/MEK/ERK signal pathways. In conclusion, TPP plays important roles in regulating cell viability and apoptosis in hypoxia-treated PC12 cells via modulating miR-34a/SIRT1, as well as activating PI3K/AKT and Ras/Raf/MEK/ERK signal pathways.

APA, Harvard, Vancouver, ISO, and other styles

42

purnama, dionisius padrawana setya, Moch Khamim, and Muhamad Fajar Subkhan. "STRATEGI DAN METODE PELAKSANAAN PEKERJAAN STRUKTUR OVERPASS PROYEK LANJUTAN PEKERJAAN AKSESIBILITAS BANDARA SOEKARNO - HATTA." Jurnal JOS-MRK 1, no. 3 (December 20, 2020): 6–12. http://dx.doi.org/10.55404/jos-mrk.2020.01.03.6-12.

Full text

Abstract:

Proyek Pembangunan Overpass Proyek Lanjutan Pekerjaan Aksesibilitas Bandara Soekarno-Hatta di kerjakan oleh PT. Wijaya Karya Tbk. dengan total panjang pekerjaan struktur 338 meter. Jembatan utama dengan bentang 150 meter. Jembatan pendekat atau oprit sepanjang 188 meter. Jembatan yang dibangun ini menghubungkan jalan perimeter selatan dan perimeter utara yang terpisah oleh jalan tol Bandara Soekarno-Hatta. Mengingat pentingnya pekerjaan struktur dalam proses pembangunan overpass ini maka penyusunan strategi dan metode pelaksanaan yang digunakan akan menunjang proses pembangunan sesuai dengan target waktu, biaya dan target mutu yang sesuai dengan dokumen kontrak yang dibuat. Tujuan dari studi ini adalah untuk membuat strategi dan metode pelaksanaan pekerjaan struktur sebagai alat bantu untuk mengetahui detai proyek tersebut dilaksanakan dengan bantuan pembuatan diagram alir pelaksanaan disertai rincian kebutuhan alat, tenaga, dan material yang akan dipakai sesuai urutan pekerjaan. Item pekerjaan yang dilakukan dalam proses pembangunan struktur overpass ini yaitu pekerjaan pondasi, pier, abutment, box girder, pile slab, aspal, dan parapet median. Dalam Pembangunan Overpass Proyek Lanjutan Pekerjaan Aksesibilitas Bandara Soekarno-Hatta ini, didapatkan durasi waktu yang dibutuhkan 365 hari dangan jam kerja yang direncanakan selama 8 jam dengan pembagian dua zona kerja utara dan selatan jembatan dengan total rencana anggaran biaya pelaksanaan sebesar Rp. 154.254.670.000,00 termasuk PPN 10%.

APA, Harvard, Vancouver, ISO, and other styles

43

O'Donnell, Barry. "Obituary all heart—Mark M. Ravitch." Journal of Pediatric Surgery 25, no. 1 (January 1990): 184. http://dx.doi.org/10.1016/s0022-3468(05)80254-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Killadi, B., R. Chaurasia, D. K. Shukla, and A. Dikshit. "Physio-chemical properties and pigment changes in the pericarp of mango cultivars during storage and ripening." Journal of Environmental Biology 39, no. 3 (May 1, 2018): 373–78. http://dx.doi.org/10.22438/jeb/39/3/mrn-348.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Li, Manqing, Su Sien Ong, Bartek Rajwa, Vivian T. Thieu, Robert L. Geahlen, and Marietta L. Harrison. "The SH3 Domain of Lck Modulates T-Cell Receptor-Dependent Activation of Extracellular Signal-Regulated Kinase through Activation of Raf-1." Molecular and Cellular Biology 28, no. 2 (November 12, 2007): 630–41. http://dx.doi.org/10.1128/mcb.00150-07.

Full text

Abstract:

ABSTRACT Engagement of the T-cell antigen receptor (TCR) results in the proximal activation of the Src family tyrosine kinase Lck. The activation of Lck leads to the downstream activation of the Ras/Raf/MEK/ERK signaling pathway (where ERK is extracellular signal-related kinase). Under conditions of weak, but not strong, stimulation through the TCR, a version of Lck that contains a single point mutation in the SH3 (Src homology 3) domain (W97ALck) fails to support the activation of ERK, despite initiating signaling through the TCR, as demonstrated by the robust activation of ZAP-70, PLC-γ, and Ras. We determined that the signaling lesion in W97ALck-expressing cells lies at the level of Raf-1 activation and is dependent on the presence of tyrosines 340/341 in the Raf-1 sequence. These data demonstrate a second function for Lck in TCR-mediated signaling to ERK. Additionally, we found that a significant fraction of Lck is localized to the Golgi apparatus and that, compared with wild-type Lck, W97ALck displays aberrant Golgi membrane localization. Our results support a model where under conditions of weak stimulation through the TCR, in addition to activated Ras, Golgi apparatus-localized Lck is needed for the full activation of Raf-1.

APA, Harvard, Vancouver, ISO, and other styles

46

Rackow, Ashley R., Jennifer L. Judge, Collynn F. Woeller, Patricia J. Sime, and Robert M. Kottmann. "miR-338-3p blocks TGFβ-induced myofibroblast differentiation through the induction of PTEN." American Journal of Physiology-Lung Cellular and Molecular Physiology 322, no. 3 (March 1, 2022): L385—L400. http://dx.doi.org/10.1152/ajplung.00251.2021.

Full text

Abstract:

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease. The pathogenesis of IPF is not completely understood. However, numerous genes are associated with the development and progression of pulmonary fibrosis, indicating there is a significant genetic component to the pathogenesis of IPF. Epigenetic influences on the development of human disease, including pulmonary fibrosis, remain to be fully elucidated. In this paper, we identify miR-338-3p as a microRNA severely downregulated in the lungs of patients with pulmonary fibrosis and in experimental models of pulmonary fibrosis. Treatment of primary human lung fibroblasts with miR-338-3p inhibits myofibroblast differentiation and matrix protein production. Published and proposed targets of miR-338-3p such as TGFβ receptor 1, MEK/ERK 1/2, Cdk4, and Cyclin D are also not responsible for the regulation of pulmonary fibroblast behavior by miR-338-3p. miR-338-3p inhibits myofibroblast differentiation by preventing TGFβ-mediated downregulation of phosphatase and tensin homolog (PTEN), a known antifibrotic mediator.

APA, Harvard, Vancouver, ISO, and other styles

47

Conover, Joanne. "Genetic engineering of animals: An agricultural perspective, edited by J. Warren Evans and Alexander Hollaender; Plenum Press, New York, 1986, 328 pp. $49.50." Gamete Research 16, no. 1 (January 1987): 93. http://dx.doi.org/10.1002/mrd.1120160111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Jacobsen, Douglas. "Mark Gornik, Word Made Global: Stories of African Christianity in New York City (Grand Rapids, MI: Eerdmans, 2011), pp. xiii + 348. $30.00 (pbk)." Scottish Journal of Theology 67, no. 3 (June 26, 2014): 375–76. http://dx.doi.org/10.1017/s0036930612000609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wüstenberg, Ralf K. "The Qur'an in Context: A Christian Exploration, Mark Robert Anderson, IVP, 2016 (ISBN 978-0-8308-5142-3), xx + 348 pp., pb $30." Reviews in Religion & Theology 25, no. 4 (October 2018): 617–20. http://dx.doi.org/10.1111/rirt.13355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Green, William. "Reviews." Leading Edge 40, no. 11 (November 2021): 859–60. http://dx.doi.org/10.1190/tle40110859.1.

Full text

Abstract:

The Gulf of Mexico Sedimentary Basin: Depositional Evolution and Petroleum Applications, by John W. Snedden and William E. Galloway, ISBN 978-1-108-41902-4, 2019, Cambridge University Press, 318 p. 100% Clean, Renewable Energy and Storage for Everything, by Mark Z. Jacobson, ISBN 978-1-108-47980-6, 2020, Cambridge University Press, 442 p.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!